Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15986887 | 0.86 | PTGS1 (0.44) | PTGS1HDAC1MAPKAPK2GSK3BDYRK1A | |
| SCHEMBL7908261 | 0.85 | GAA (0.45) | PTGS1HDAC1MAPKAPK2GSK3BDYRK1A | |
| SCHEMBL31165993 | 0.85 | GAA (0.45) | PTGS1HDAC1MAPKAPK2GSK3BDYRK1A | |
| SCHEMBL13403361 | 0.83 | PTGS1 (0.51) | PTGS1MAPTRAB9A | |
| SCHEMBL6609814 | 0.83 | NAMPT (0.52) | HDAC1MAPKAPK2GSK3BDYRK1ANAMPT | |
| SCHEMBL1126145 | 0.83 | RAB9A (0.62) | GSK3BDYRK1AMAPTRAB9A | |
| SCHEMBL851343 | 0.83 | DEGS1 (0.56) | GSK3BDYRK1ANAMPTGRIN2B | |
| SCHEMBL5734042 | 0.82 | NNMT (0.58) | HDAC1GSK3BDYRK1ANAMPTGRIN2B | |
| SCHEMBL8362974 | 0.81 | HDAC1 (0.53) | HDAC1MAPKAPK2GSK3BDYRK1ANAMPT | |
| SCHEMBL4398253 | 0.81 | GSK3B (0.44) | HDAC1MAPKAPK2GSK3BDYRK1ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025229624-A2 | NEW CD38 INHIBITORS | NAPA THERAPEUTICS LIMITED (GB) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025226545-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| WO-2025108234-A1 | COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦药物研究院有限公司 | 2025-05-30 | — | — | WO | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025059469-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS AKT INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2003011872-A1 | PLATELET ADP RECEPTOR INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020077486-A1 | For therapy and prophylaxis of thrombosis in a mammal | ALEXION PHARMACEUTICALS, INC. | 2002-06-20 | — | — | US | disclosed |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6297248-B1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | SUNTORY LIMITED (JP) | 2001-10-02 | — | — | US | disclosed |
| US-6268378-B1 | TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH. | MERCK & CO., INC. | 2001-07-31 | — | — | US | disclosed |
| CN-1284955-A | Integrin receptor antagonists | MERCK & CO INC (US) | 2001-02-21 | — | — | CN | disclosed |
| US-6066648-A | USEFUL IN INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH | MERCK & CO., INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-6017926-A | Integrin receptor antagonists | MERCK & CO., INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0958297-A1 | 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR | SUNTORY LIMITED (JP) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999007704-A1 | 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR | SUNTORY LIMITED (JP) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | PTGS1 1077/4885HDAC1 398/4885MAPKAPK2 337/4885 |
| US-20020077486-A1 | For therapy and prophylaxis of thrombosis in a mammal | PIGS, TBXA2R, GP6 | PTGS1 231/4885HDAC1 1801/4885MAPKAPK2 3141/4885 |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | PDE3A, PDE5A, PDE3B | PTGS1 250/4885HDAC1 77/4885MAPKAPK2 2907/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | PTGS1 1077/4885HDAC1 398/4885MAPKAPK2 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.